drugset
Drugs / SKI-O-703
last change Jan 2023 re-read 3 minutes ago

SKI-O-703

also known as SKI-O-592

targets SYK via inhibition

Developed for
rheumatoid arthritis · thrombocytopenia due to immune destruction
Investigated by
Oscotec Inc. · PPD Development, LP

Trials 5

today NCT05042986 · Ph 0 NCT04056195 · Ph 2 NCT04057118 · Ph 2 NCT03315494 · Ph 1 NCT02717988 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05042986 Aug → Sep 2021 — Oscotec Inc. Completed No outcome recorded
Phase 12 trials
Phase 1 NCT03315494 Sep → Dec 2016 rheumatoid arthritis Oscotec Inc. Completed No outcome recorded
Phase 1 NCT02717988 Sep 2015 → Mar 2016 rheumatoid arthritis Oscotec Inc. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT04056195 Oct 2019 → Jan 2023 thrombocytopenia due to immune destruction Oscotec Inc. Completed No outcome recorded
Phase 2 NCT04057118 Mar 2019 → Oct 2020 rheumatoid arthritis Oscotec Inc. Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as SKI-O-703 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02717988 ↗
4

NCT05042986 ↗

NCT04056195 ↗

NCT04057118 ↗

NCT03315494 ↗
Known as SKI-O-592 “SKI-O-592 (the free base of SKI-O-703) has demonstrated high selectivity and potency against spleen tyrosine kinase in a biochemical assay.” NCT05042986 ↗
Action Inhibit “SKI-O-703, SYK Inhibitor” NCT04056195 ↗
Route Oral “Single Oral Dose” NCT02717988 ↗
Target SYK “SKI-O-703, SYK Inhibitor” NCT04056195 ↗